Carisma Therapeutics’ chimeric antigen receptor (CAR) macrophage CT-0508 has continued to be well-tolerated in patients with solid tumors, with promising signs of efficacy, according to updated data from a phase 1, first-in-human trial...
For a moment there, it seemed as though a reverse merger between Carisma Therapeutics and Sesen Bio was on thin ice. Activist investors at the latter were holding up the marriage, largely to...
Carisma Therapeutics became the Philadelphia region's latest publicly traded life sciences company earlier this month after it completed a reverse-merger with Sesen Bio.
A novel monocyte-derived cell therapy showed evidence of migrating from the blood to the tumor microenvironment for several solid tumor types, according to phase 1 study results.